Erivedge

What Erivedge Means in Everyday Medical Language

Erivedge is the brand name for the drug vismodegib, also known as GDC-0449. It is a medication used to treat a type of skin cancer called basal cell carcinoma (BCC). Specifically, it is prescribed when the cancer has spread to other parts of the body, has returned after surgery, or cannot be treated with surgery or radiation. Erivedge works by blocking a protein involved in the Hedgehog signaling pathway, which plays a role in tissue growth and repair. By blocking this pathway, the drug may help stop or slow the growth of cancer cells.

Why Erivedge Can Matter in Cancer Care

Basal cell carcinoma is a common skin cancer that usually can be treated with surgery or radiation. However, in some cases, the cancer spreads or comes back, making these treatments less effective or not possible. Erivedge offers a treatment option for these situations by targeting the specific biological pathway that helps the cancer grow. It was the first drug approved by the U.S. Food and Drug Administration (FDA) that targets the Hedgehog signaling pathway, marking an important step in targeted cancer therapies.

What Patients Might See or Hear About Erivedge

Patients may come across the name Erivedge, vismodegib, or GDC-0449 in medical records, treatment plans, or discussions with their healthcare team. It might also appear in information about clinical trials or drug guides. Because the drug has several names, it can be confusing. Patients might hear about possible side effects such as nausea, muscle spasms, fatigue, hair loss, or changes in taste. It’s important to discuss any questions or concerns about the drug’s effects and how it fits into the overall treatment plan with the care team.

Where Erivedge Might Appear in Cancer Care

Erivedge may be mentioned in a variety of places including pathology reports, treatment summaries, clinical trial listings, or drug information sheets. It is specifically noted in cases of advanced basal cell carcinoma that cannot be managed by surgery or radiation. It may also be discussed as part of ongoing research for other cancers, though its approved use is currently for basal cell carcinoma.

Common Confusions and How to Understand Erivedge

Because Erivedge is also called vismodegib or GDC-0449, patients may find different names in their records or online. This can cause confusion, but all these names refer to the same drug. It’s important not to assume that seeing the name alone means a specific diagnosis or treatment plan. Instead, ask your healthcare provider how this drug relates to your individual care. Also, Erivedge is not a cure for all basal cell carcinomas or other cancers; it is one treatment option for certain cases.

Questions to Ask Your Care Team About Erivedge

If you see Erivedge mentioned, consider asking your care team what role this drug plays in your treatment. Questions might include: Why is this drug recommended or prescribed? What are the possible benefits and side effects? How will the drug be given and for how long? Are there clinical trials involving this drug that might be relevant? Understanding these points can help you feel more informed and involved in your care.

Reading Erivedge in Context

When you encounter the term Erivedge, it’s best to view it as part of a larger treatment discussion rather than a standalone label. It is a medication name, not a diagnosis. Its presence in a report or plan means your care team is considering or using this drug as part of managing basal cell carcinoma. Always ask for clarification about how it fits your personal situation.

Safety and Next Steps

This information is educational and does not replace medical advice. Erivedge may not be suitable or safe for everyone, and decisions about its use depend on individual health factors. If you see this term in your medical records or hear it from your care team, the best next step is to ask them directly what it means for you. They can explain how this drug fits into your treatment and what to expect.